Introduction: Peripheral nerve microneurolysis is a neurosurgical procedure used to relieve nerve compression and injuries, frequently indicated for compressive neuropathies. In Brazil, this procedure is available through the Unified Health System (SUS), highlighting the importance of evaluating its financial and clinical impacts due to high demand and associated costs.
Methods: Initially, files from the SUS Hospital Information System (SIH/SUS) covering the period from January 2008 to August 2024 were accessed via the Datasus website. The files were analyzed to identify characteristics such as records of Hospitalization Authorizations (AIHs), hospitalizations, financial values, and clinical outcomes. Variables of interest included hospital and professional costs, federal and local management contributions, and indicators of hospital stay and mortality. Next, frequencies of microneurolysis, total procedural costs with allocation details, average length of stay per hospitalization, number of deaths, and the mortality rate over the study period were determined.
Results: Between 2008 and 2024, 35,936 AIHs were approved for peripheral nerve microneurolysis, totaling 35,936 hospitalizations. The total cost of the procedure reached R$ 29,599,291.18, with R$ 21,475,256.32 allocated to hospital services and R$ 7,756,165.14 to professional services. The average cost per AIH and per hospitalization was R$ 823.67. The study period accounted for 44,975 hospitalization days, with an average stay of 1.3 days. There were 5 deaths associated with the procedure, resulting in a mortality rate of 0.01%.
Conclusion : Peripheral nerve microneurolysis within the SUS proved efficient, with low mortality rates (0.01%), short hospital stays (1.3 days), and affordable costs (R$ 823.67 per hospitalization). These results suggest feasibility within the public health system, though ongoing monitoring of costs and outcomes remains essential for resource optimization.
.jpg)